8 withdrawn. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Withdrawn 8 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation Study of New Compounds With Potential Use in Schizophrenia URB597, intranasal Insulin, Cannabidiol CR - Schizophrenia | Phase 1 | Withdrawn | Central Institute of Mental Health, Mannheim | 2025-01-31 | 2025-03-21 | |
| Brain Biomarker on Inflammation Response LPS, Placebo - Schizophrenia | Phase 1 | Withdrawn | University of Maryland, Baltimore | 2025-01-01 | 2023-12-05 | |
| A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia Brexpiprazole LAI: Dose 1, Brexpiprazole LAI: Dose 2, Brexpiprazole LAI: Dose 3 - Schizophrenia | Phase 1 | Withdrawn | Otsuka Pharmaceutical Co., Ltd. | 2021-11-22 | 2022-04-28 | |
| Nicotinic Receptors and Schizophrenia Risperidone plus Placebo, Risperidone plus DMXB-A - Schizophrenia | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2015-08-01 | 2017-05-30 | |
| Phosphatidylcholine Supplementation in Infants phosphatidylcholine supplementation, placebo - Schizophrenia, Diminished P50 Sensory Gating | Phase 1 / Phase 2 | Withdrawn | University of Colorado, Denver | 2013-09-01 | 2020-09-02 | |
| Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in Schizophrenia Deep Brain Stimulation - Schizophrenia; Negative Type | Phase 1 | Withdrawn | Centre for Addiction and Mental Health | 2012-09-01 | 2015-08-03 | |
| Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder NSA-789, Placebo - Schizophrenia | Phase 1 | Withdrawn | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-05-01 | 2021-08-20 | |
| Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients NSA-789 at 2 different doses - Schizophrenia | Phase 1 | Withdrawn | Wyeth is now a wholly owned subsidiary of Pfizer | 2009-01-01 | 2021-08-20 |
Brain Diseases (1) · Mental Disorders (1) · Neurologic Manifestations (1) · Signs and Symptoms (1)
Schizophrenia Spectrum and Other Psychotic Disorders (8) · Mental Disorders (7) · Central Nervous System Diseases (1) · Nervous System Diseases (1) · Pathological Conditions, Signs and Symptoms (1)
3-(2,4-dimethoxybenzylidene)anabaseine (1) · Corn Oil (1) · Deep Brain Stimulation (1) · Phosphatidylcholines (1) · Risperidone (1) · cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (1)
Wyeth is now a wholly owned subsidiary of Pfizer (2) · Central Institute of Mental Health, Mannheim (1) · Centre for Addiction and Mental Health (1) · Otsuka Pharmaceutical Co., Ltd. (1) · University of Colorado, Denver (1) · University of Maryland, Baltimore (1) · VA Office of Research and Development (1)
United States (4) · Canada (1) · France (1) · Germany (1)
Robert Freedman, MD (2) · F. Markus Leweke, MD (1) · L E Hong, M.D. (1) · Takehisa Matsumaru (1) · Zafiris J Daskalakis, MD, PhD (1)